Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AAD Roundup: Sun Sets Sights On Psoriasis As Competitive Pressures Mount

Executive Summary

Sun presented new data on its IL-23 inhibitor tildrakizumab, pending US FDA approval, at the American Academy of Dermatology meeting. Novartis and others – all competing for payers' dollars – also try to make the case for their products.

Advertisement

Related Content

Celgene’s Positive Phase III Data For Otezla In Scalp Psoriasis Could Yield Broader Label
Interview: UCB Sees Bimekizumab As Good Long-Term Bet
Celgene's Terrie Curran On Building, Broadening The I&I Franchise
New Dawn At Novartis As Narasimhan Demands Breakthroughs
US Pricing Squeeze Clouds Sun Pharma Q2; Site Re-Inspection Critical
Is Triple Phase III Triumph for AbbVie's Risankizumab In Psoriasis Good Enough?
UCB's Bimekizumab Could Struggle With Saturated Psoriasis Market
LEO Pharma Gets EU Go-Ahead For Psoriasis Latecomer Brodalumab
Sponsors Flesh Out Profiles of New Dermatology Drugs At AAD Meeting
AstraZeneca Hands LEO Dermatology Potential

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100444

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel